Abstract

INTRODUCTION:

The aim of this study is to characterize health related quality of life (HRQOL) in Japanese patients after bladder cancer surgery and to perform cross-cultural comparison between Japanese and American patients.

METHODS:

Firstly, we cross-sectionally assessed HRQOL of 371 patients in Japan using the Bladder Cancer Index (BCI-Japanese). HRQOL of the four groups of patients (native bladder without intravesical therapy, native bladder with intravesical

therapy, cystectomy with ileal conduit, and cystectomy with neobladder) were assessed. Secondly, we compared the Japanese with the American cohort (n = 315) from the original BCI paper. After adjusting for age and gender, the differences in each BCI subdomain score was analyzed.

RESULTS:

Among Japanese patients, the urinary domain function score was significantly lower among the cystectomy with neobladder group, compared to the cystectomy with ileal conduit group (p < 0. 01). Despite this, the urinary bother was comparable between the two groups. Although there were apparent differences between Japanese and American patients, there were few differences in Urinary and Bowel HRQOL. In three of the four treatment groups (other than native bladder with intravesical therapy), Japanese patients were more likely than Americans to report poor sexual function (p < 0.05). However, Japanese patients were less likely than Americans to be bothered by their lower sexual function, regardless of treatment (p < 0.05).

CONCLUSIONS:

HRQOL outcomes following treatment of bladder cancer in Japan are comparable to those in the USA, except for sexual functioning and sexual bother. The BCI can be used for cross-cultural assessments of HRQOL in bladder cancer patients.

中文翻译：

---

用最新开发的日文版膀胱癌指数衡量的日美膀胱癌患者与健康相关的生活质量比较

摘要

介绍：

这项研究的目的是表征膀胱癌手术后日本患者的健康相关生活质量（HRQOL），并在日本和美国患者之间进行跨文化比较。

方法：

首先，我们使用膀胱癌指数（BCI-日语）对日本371名患者的HRQOL进行了横断面评估。四组患者的HRQOL（未行膀胱内治疗的原发膀胱，未行膀胱内治疗的原发膀胱

治疗，回肠导管膀胱切除术和新膀胱膀胱切除术）进行了评估。其次，我们 从原始BCI论文中比较了日本人和美国人（n = 315）。在调整了年龄和性别之后，分析了每个BCI子域得分的差异。

结果：

在日本患者中，新膀胱组膀胱切除术的尿路功能评分明显低于回肠导管组膀胱切除术（p  <0. 01）。尽管如此，两组的泌尿麻烦程度相当。尽管日本和美国患者之间存在明显差异，但尿液和肠HRQOL差异很小。在四个治疗组中的三个中（除了膀胱内治疗除外），日本患者比美国人更容易报告性功能差（p  <0.05）。然而，无论采用何种治疗方法，日本患者都比其美国人受较低的性功能困扰的可能性小（p  <0.05）。

结论：

除了性功能和性困扰之外，日本治疗膀胱癌后的HRQOL结果与美国相当。BCI可用于膀胱癌患者中HRQOL的跨文化评估。